tracken
Bristol-Myers Squibb Aktie News
Positiv
Market Watch
●
etwa 16 Stunden alt
Bristol Myers' stock rallied Wednesday as investors maintained high hopes for Cobenfy as an Alzheimer's treatment, even though the outcome of a late-stage trial has been delayed.
Neutral
Business Wire
●
etwa 19 Stunden alt
LOS ANGELES--(BUSINESS WIRE)-- #biotech--Terray Reaches Milestone in Collaboration with Bristol Myers Squibb.
Positiv
Investors Business Daily
●
etwa 20 Stunden alt
Bristol Myers Squibb stock popped Wednesday after the firm delayed a study testing Cobenfy in Alzheimer's disease psychosis.
Positiv
Barrons
●
etwa 21 Stunden alt
The drugmaker is testing its antipsychotic drug Cobenfy for the treatment of psychosis associated with Alzheimer's disease.
Neutral
Business Wire
●
etwa 23 Stunden alt
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease.
Positiv
Market Watch
●
ein Tag alt
John Buckingham, editor of the Prudent Speculator, reminds investors to be “willing to stomach volatility.”
Negativ
Reuters
●
3 Tage alt
A U.S. judge on Monday rejected Bristol Myers Squibb's bid to dismiss a $6.7 billion lawsuit claiming it cheated shareholders of the former Celgene by delaying federal approval for three drugs, including the cancer treatment Breyanzi, by specified deadlines.
Positiv
Forbes
●
3 Tage alt
Bristol Myers Squibb (BMY) is finally showing signs of life. The stock has climbed 7.3% over the last five days, adding roughly $7 billion in market value — pushing its market cap back toward $100 billion.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
